All News Imugene Limited

Equities

IMU

AU000000IMU9

Market Closed - Australian S.E. Other stock markets 11:40:21 24/06/2024 am IST			5-day change	1st Jan Change
0.055 ^AUD	-6.78%		-5.17%	-50.00%

06:43am	Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%	MT
16/04	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%	10:13am	MT
Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million	16/04	AQ
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	16/04	MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	16/04	CI
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort	16/04	AQ
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	16/04	CI
Imugene opens enrolment for Bile Tract Cancer expansion study	15/04	AQ
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study	15/04	MT
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024	09/04	AQ
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	04/04	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	20/03	MT
Imugene progresses onCARlytics solid tumour trial to combination arm	11/03	AQ
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment	11/03	AQ
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	11/03	CI
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment	11/03	MT
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	29/02	MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	29/02	MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts	22/02	AQ
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial	15/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Imugene Limited

Equities

IMU

AU000000IMU9

All News

Filters